Newbold

Newbold Therapeutics is a private biotechnology company focused on developing next-generation treatments for chronic pain and pruritus. The company leverages its expertise in ion channel modulation to design highly selective small molecules targeting Nav1.7 and Nav1.8, which are critical mediators of pain signaling in the peripheral nervous system. By focusing on peripheral targets, Newbold aims to provide potent analgesic and anti-pruritic effects while avoiding the central nervous system side effects and addiction risks associated with opioids. The company's lead programs are currently in the pre-clinical stage, targeting rare and common conditions characterized by severe pain and itching.